Kisspeptin for Metabolic Diseases

Phase-Based Progress Estimates
Massachusetts General Hospital, Boston, MA
Metabolic Diseases
Kisspeptin-10 - Drug
18 - 65
What conditions do you have?

Study Summary

The goal of this study is to understand how exogenous kisspeptin affects metabolism by evaluating responses to an hyperglycemic clamp

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

2 Primary · 0 Secondary · Reporting Duration: 10 minutes

10 minutes
First Phase Insulin Secretion
2 hours
Second Phase Insulin Secretion

Trial Safety

Safety Progress

1 of 3

Trial Design

2 Treatment Groups

1 of 2
1 of 2
Experimental Treatment
Non-Treatment Group

12 Total Participants · 2 Treatment Groups

Primary Treatment: Kisspeptin · Has Placebo Group · Phase 1

KisspeptinExperimental Group · 2 Interventions: Kisspeptin-10, Hyperglycemic Clamp · Intervention Types: Drug, DiagnosticTest
PlaceboPlaceboComparator Group · 2 Interventions: Hyperglycemic Clamp, Placebo · Intervention Types: DiagnosticTest, Drug
First Studied
Drug Approval Stage
How many patients have taken this drug
Completed Phase 3
Hyperglycemic Clamp
Completed Phase 4

Trial Logistics


Participation is compensated

You will be compensated for participating in this trial.

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 10 minutes

Trial Background

Prof. Stephanie B. Seminara, MD
Principal Investigator
Massachusetts General Hospital
Closest Location: Massachusetts General Hospital · Boston, MA
Photo of Massachusetts General Hospital  1Photo of Massachusetts General Hospital  2Photo of Massachusetts General Hospital  3
1993First Recorded Clinical Trial
5 TrialsResearching Metabolic Diseases
2425 CompletedClinical Trials

Eligibility Criteria

Age 18 - 65 · Female Participants · 10 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have normal pubertal development.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.